接受心房颤动消融患者的当代管理:ESC-EHRA心房颤动消融长期登记研究的院内及1年随访结果
ESC-EHRA心房颤动消融长期登记研究是一项前瞻性多国研究,纳入27个欧洲国家104个中心的3630例患者,其中3593例(98.9%)接受房颤消融。院内并发症发生率为7.8%,1年随访时(中位12.4个月)成功率为73.6%,46%的患者仍在使用抗心律失常药物,消融后监测和抗血栓治疗存在较大差异且指南依从性不足。
要点
- 肺静脉隔离尝试率为98.8%,实现率为95-97%。
- 院内并发症发生率为7.8%,1例死亡与房食管瘘相关。
- 1年成功率(伴或不伴抗心律失常药物)为73.6%,46%仍在用药。
核心结论
- 临床实践中房颤消融多用于有症状、相对年轻且其他方面健康的患者,总体成功率满意,但并发症发生率仍较高,且相当比例患者仍在使用抗心律失常药物。
- 消融后监测存在较大差异,抗血栓治疗对指南的依从性不足。
研究设计与样本
- ESC-EHRA心房颤动消融长期登记研究为前瞻性多国研究,27个欧洲国家104个中心参与,要求各中心连续入组20-50例计划行首次或再次房颤消融的患者。
- 共纳入3630例患者,其中3593例(98.9%)接受了房颤消融;中位年龄59岁,32.4%患者为孤立性心房颤动。
- 术前、术中及1年随访数据通过基于网络的电子病例报告表采集。
主要发现
- 肺静脉隔离尝试率为98.8%,实现率为95-97%;97%的患者存在房颤相关症状。
- 院内并发症发生率为7.8%,1例患者因房食管瘘死亡。
- 1年随访在3180例(88.6%)患者中完成,中位随访时间为12.4个月(11.9-13.4),其中52.8%通过临床访视、44.2%通过电话联系、3.0%通过全科医生联系完成。
- 12个月时,伴或不伴抗心律失常药物的成功率为73.6%;46%的患者仍在使用抗心律失常药物。
- 晚期并发症包括额外14例死亡(4例心脏性、4例血管性、6例其他原因)和333例(10.7%)其他并发症。
关键数值与推荐
- 肺静脉隔离尝试率98.8%,实现率95-97%。
- 院内并发症发生率7.8%,1年随访期间其他并发症发生率10.7%。
- 12个月成功率(伴或不伴抗心律失常药物)为73.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The ESC-EHRA Atrial Fibrillation Ablation Long-Term registry is a prospective, multinational study that aims at providing an accurate picture of contemporary real-world ablation for atrial fibrillation (AFib) and its outcome. METHODS AND RESULTS: A total of 104 centres in 27 European countries participated and were asked to enrol 20-50 consecutive patients scheduled for first and re-do AFib ablation. Pre-procedural, procedural and 1-year follow-up data were captured on a web-based electronic case record form. Overall, 3630 patients were included, of which 3593 underwent an AFib ablation (98.9%). Median age was 59 years and 32.4% patients had lone atrial fibrillation. Pulmonary vein isolation was attempted in 98.8% of patients and achieved in 95-97%. AFib-related symptoms were present in 97%. In-hospital complications occurred in 7.8% and one patient died due to an atrioesophageal fistula. One-year follow-up was performed in 3180 (88.6%) at a median of 12.4 months (11.9-13.4) after ablation: 52.8% by clinical visit, 44.2% by telephone contact and 3.0% by contact with the general practitioner. At 12-months, the success rate with or without antiarrhythmic drugs (AADs) was 73.6%. A significant portion (46%) was still on AADs. Late complications included 14 additional deaths (4 cardiac, 4 vascular, 6 other causes) and 333 (10.7%) other complications. CONCLUSION: AFib ablation in clinical practice is mostly performed in symptomatic, relatively young and otherwise healthy patients. Overall success rate is satisfactory, but complication rate remains considerable and a significant portion of patients remain on AADs. Monitoring after ablation shows wide variations. Antithrombotic treatment after ablation shows insufficient guideline-adherence.
引用
- Arbelo E, Brugada J, Blomström-Lundqvist C, et al. Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. Eur Heart J. 2017. PMID: 28104790. doi:10.1093/eurheartj/ehw564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。